Avalon GloboCare Corp.
ALBT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ALBT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ALBT
Avalon GloboCare Corp. (ALBT) is a biotechnology and technology company that has shifted its focus from cellular therapy to advancing next-generation Agentic AI systems, including automated video generation and small business marketing automation solutions, while facing significant financial challenges and a going concern qualification.
Key risk: Going concern uncertainty
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Avalon GloboCare Corp. (ALBT) is a biotechnology and technology company that has shifted its focus from cellular therapy to advancing next-generation Agentic AI systems, including automated video generation and small business marketing automation solutions, while facing significant financial challenges and a going concern qualification.
- Avalon GloboCare has suspended all research and development efforts related to cellular therapy to preserve cash and focus on product commercialization [sec_mda · as of 2026-05-11].
- The company is advancing next-generation Agentic AI systems, including automated video generation and small business marketing automation solutions [sec_mda · as of 2026-05-11].
- As of June 30, 2026, the company reported cash and equivalents of $0.0M, net income of -$2.2M, shareholders' equity of $7.1M, and total debt of $1.2M [sec].
- The company had a working capital deficit of approximately $2,774,000 as of the most recent reporting period [sec_mda · as of 2026-05-11].
- Avalon GloboCare's condensed consolidated financial statements have been prepared assuming the company will continue as a going concern [sec_mda · as of 2026-05-11].
What works
- The company is pivoting to next-generation Agentic AI systems, which may open new revenue streams in automated video generation and small business marketing automation [sec_mda · as of 2026-05-11].
- By suspending cellular therapy R&D, the company is focusing resources on product commercialization, potentially accelerating time to market [sec_mda · as of 2026-05-11].
What to weigh
- The company has a working capital deficit of approximately $2,774,000 and a going concern qualification, indicating substantial doubt about its ability to continue operations [sec_mda · as of 2026-05-11].
- Cash and equivalents were $0.0M as of June 30, 2026, with no credit facilities in place, raising significant financing risk [sec] [sec · filed 2026-07-13].
- The company has outstanding indebtedness of approximately $1.38 million as of March 31, 2026, which could adversely affect financial condition and liquidity [sec · filed 2026-07-13].
- Avalon GloboCare has incurred recurring net losses and negative cash flow from operations, and expects cash used in operating activities to increase [sec_mda · as of 2025-11-14] [sec · filed 2026-07-13].
From the filings
Quoted directly from source documents.
The company has suspended all cellular therapy R&D to focus on AI commercialization.
“In order to preserve cash and focus on product commercialization, we have suspended all research and development efforts related to cellular therapy.”
SEC MD&A · May 11, 2026
The company is advancing next-generation Agentic AI systems.
“we are advancing next-generation Agentic AI systems, including automated video generation and small business marketing automation solutions.”
SEC MD&A · May 11, 2026
The company has a working capital deficit and going concern uncertainty.
“we had working capital deficit of approximately $2,774,000 at”
SEC MD&A · May 11, 2026
The company has no credit facilities and may need to curtail operations if unable to raise capital.
“We have no arrangements or credit facilities currently in place as a source of funds, and there can be no assurance that we will be able to raise sufficient additional capital on acceptable terms, or at all.”
SEC filings · July 13, 2026
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — The company's financial statements are prepared assuming it will continue as a going concern, but a working capital deficit and recurring losses raise substantial doubt [sec_mda · as of 2026-05-11].
- Zero cash and no financing — Cash and equivalents were $0.0M as of June 30, 2026, with no credit facilities in place, making additional capital essential [sec] [sec · filed 2026-07-13].
- Debt burden — Outstanding indebtedness of approximately $1.38 million as of March 31, 2026 could adversely affect liquidity and financial condition [sec · filed 2026-07-13].
- Pivot execution risk — The company is shifting from cellular therapy to AI, an area where it may lack a track record, and faces competition from established players [sec_mda · as of 2026-05-11].
What to watch
- Ability to raise additional capital given zero cash and no credit facilities [sec · filed 2026-07-13].
- Progress in commercializing next-generation Agentic AI systems, including automated video generation and small business marketing automation [sec_mda · as of 2026-05-11].
- Changes in working capital deficit and going concern status in future filings [sec_mda · as of 2026-05-11].
- Any updates on debt repayment or restructuring given outstanding indebtedness of $1.38 million [sec · filed 2026-07-13].
Sources: SEC filings · SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run Avalon GloboCare Corp. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Avalon GloboCare Corp. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
0.8 months
D/E 0.46 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
17
Total value held
$187K
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 114,650 | $61K |
| geode capital management, llc | 61,949 | $33K |
| citadel advisors llc | 56,184 | $30K |
| morgan stanley | 27,604 | $15K |
| stonex group inc. | 20,000 | $11K |
| vanguard fiduciary trust co | 18,394 | $10K |
| xtx topco ltd | 17,319 | $9K |
| two sigma securities, llc | 15,340 | $8K |
| jones financial companies lllp | 10,000 | $5K |
| ubs group ag | 5,536 | $3K |
Showing top 10 of 17 institutional holders of Avalon GloboCare Corp.. Open the full 13F history after sign-in.
Short Interest
as of Apr 28, 2026- % of float
- 11.7%
- Days to cover
- 0.5
- Shares short
- 926,778
- Daily short volume (May 5, 2026)
- 39.3%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ALBT short interestGovernance
Frequently asked questions
What is the AI investment thesis for Avalon GloboCare Corp.?
Avalon GloboCare Corp. (ALBT) is a biotechnology and technology company that has shifted its focus from cellular therapy to advancing next-generation Agentic AI systems, including automated video generation and small business marketing automation solutions, while facing significant financial challenges and a going concern qualification.
Who is the CEO of Avalon GloboCare Corp.?
Ms. Meng Li is the chief executive officer of Avalon GloboCare Corp. (ALBT).
Where is Avalon GloboCare Corp. headquartered?
Avalon GloboCare Corp. (ALBT) is headquartered in Freehold, NJ, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.